AKT2-knockdown suppressed viability with enhanced apoptosis, and attenuated chemoresistance to temozolomide of human glioblastoma cells in vitro and in vivo
Authors:
Open Access
- 1 July 2015
- journal article
- research article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. 8, 1681-1690
Abstract
The AKT2 kinase (protein kinase Bβ) is overexpressed in high-grade gliomas. Upregulation of the AKT2 gene has been previously observed in glioblastoma patients suffering from chemotherapy failure and tumor progress. In this study, we aimed to evaluate the effect of AKT2 on viability and chemoresistance in the human glioblastoma cell line U251. The U251 cell line was stably transfected with short hairpin RNA (shRNA) targeting AKT2. U251 cells underexpressing AKT2 were then examined for viability with temozolomide (TMZ) treatment, and tested for cell apoptosis both in vitro and in tumor-implanted mice. Next, expressions of several chemoresistance-related molecules were measured by quantitative reverse-transcription polymerase chain reaction (qRT-PCR) and western blot analysis. The results showed that the 50% inhibitory concentration (IC50) of AKT2 shRNA-transfected cells was significantly lower compared with Lenti-GFP-transfected and nontransfected controls and that the tumor growth of the AKT2-shRNA and TMZ combined-treated mice was obviously suppressed in either mass or volume. Concomitantly, the apoptosis of TMZ-treated tumor cells was significantly enhanced after knockdown of AKT2, as measured by flow cytometry and in situ terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) analysis. Furthermore, AKT2-inhibition in TMZ-treated glioblastoma U251 cells upregulated apoptotic effector caspase-3, whereas it downregulated antiapoptotic protein Bcl-2, DNA repairing protein MGMT, and drug efflux pump protein MRP1. Our study identified AKT2 as an important gene in presenting chemoresistance in glioblastoma, and a potential target to potentiate the clinical effect of chemotherapy in glioma treatment.Keywords
This publication has 21 references indexed in Scilit:
- Faculty Opinions recommendation of Overexpression and overactivation of Akt in thyroid carcinoma.2015
- PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcomeNeuro-Oncology, 2012
- Recent advances in the molecular understanding of glioblastomaJournal of Neuro-Oncology, 2012
- Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant GliomaCA: A Cancer Journal for Clinicians, 2010
- Akt Signaling and Cancer: Surviving but not Moving OnCancer Research, 2006
- Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancerInternational Journal of Cancer, 2003
- High expression levels of nuclear factor κB, IκB kinase α and Akt kinase in squamous cell carcinoma of the oral cavityCancer, 2001
- Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA.Proceedings of the National Academy of Sciences, 1996
- Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomasInternational Journal of Cancer, 1995
- AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas.Proceedings of the National Academy of Sciences, 1992